Celgene, through its wholly owned subsiduary Anthrogenesis (now called Celgene Cellular Therapeutics) has been active in the cord blood IP area, through patents covering innovative methods of extracting stem cells from the placental matrix itself . In the current patent, Celgene covers a kit for collecting not only the...
Stem cells are usually identified based on markers such as CD34 for hematopoietic stem cells, or CD133 for cancer stem cells, or specific properties such as expression of aldehyde dehydrogenase. Interestingly, in this patent the morphological characteristics of the stem cell are covered...
The use of bone marrow mononuclear cells as a source of stem cells has been widely described in numerous medical procedures ranging from stimulation of angiogenesis in patients with peripheral artery disease to treatment of terminal liver failure, to treatment of
One of the major technological advances that allowed for the characterization and use of stem cells was the development of defined monoclonal antibodies that repeatedly attached to markers on stem cells. For example, the patents covering the original hematopoietic stem cells used monoclonal antibodies to actually identify the...
The current patent covers the nucleic acid sequences for promoters. In the claims it just states "promoters" but the specification teaches that the promoters are specific to "stem cells". The examples part of the patent teaches that they are active in CD34 and CD133 cells found from cord blood.
Being able to have patents on actual promoter sequences that...
This patent teaches that tumor stem cells can be extracted population of non-stem cells by selecting for the cells which have activation of the transcription factor LEF/TCF and/or the beta.-catenin pathway. This patent essentially takes a pathway that is known to be activated in non-malignant sttem cells and simply applies it to malignant stem cells. Some may...
This patent useful for parties looking for methodologies to purify mesenchymal stem cells from amniotic fluid. The patent has 3 independent claims. Essentially all three are directed towards a two step culture process where amniotic fluid cells are first grown in a vessel, subsequently non-adherent cells are isolated, and allowed to expand. The difference between the claims is the media used...
As mentioned in our discussion about patent # 7008394, bone marrow harvesting is a relatively invasive procedure. This is also very relavant for regenerative uses of bone marrow where patients with a heart attack or stroke are harvested. Accordingly there is a need to develop less invasive and increasingly sterile means of harvesting. The current patent has two independent claims covering...
Monocytes are generally known as the precursors to macrophages, cells involved in phagocytosing bacteria and injured tissue (thats why in Latin "Macrophage" apparently means "Big Eater").
However, in addition to the classical functions of monocytes, there is evidence to suggest that these cells are potent stimulators of
This patent covers a device that is capable of separating various cellular populations, or populations of particulate matter. Essentially, the device addresses the need for an easy to use, effective, and rapid method of collecting the "buffy coat" from a blood population, as well as cells within the buffy coat. The device purifies the cells using axial expansion of blood fluid components...